TOKYO, July 20, 2020 /PRNewswire/ -- Biosense Webster, Inc., part of the Johnson & Johnson Medical Devices Companies*, in collaboration with researchers at the Tokyo Medical and Dental University and CTI Clinical Trial Consulting published findings in the Journal of Cardiovascular Electrophysiology demonstrating that innovative ultrasound technology can improve patient treatment for irregular heartbeats.
This meta-analysis included 19 studies with a total of 2,186 patient subjects and demonstrated that use of ICE during catheter ablation procedures resulted in lower fluoroscopy time, lower fluoroscopy dose, and shorter procedure time, when compared to standard imaging and mapping techniques without ICE. Fluoroscopy time was reduced by up to 7 minutes, while procedure time was reduced by about 15 minutes. The impact was even more significant when physicians used ICE catheters compatible with 3D mapping systems.
Healthcare professionals agree that fluoroscopy reduction is beneficial to avoid high levels of radiation exposure during cardiac ablation. Many physicians rely on fluoroscopy for visualization during the procedure, therefore requiring the use of lead to protect themselves.
Dr. Masahiko Goya of the Tokyo Medical and Dental University and the primary author of the study stated the significance of the research for improved ablation: "Fluoroscopy reduction is important not only for patient safety by eliminating potentially hazardous exposure to radiation, but also for the safety of healthcare workers who are operating in the electrophysiology lab daily… We are pleased with the results showing improved efficiency, without compromising on safety and effectiveness."
Until now, there was no big picture view on how ICE-guidance, or real-time ultrasound imaging, contributes to efficient ablation procedures. Despite the publication of several comparative studies investigating ICE, this is the first meta-analysis to consolidate the results. ICE provides enhanced visualization of the heart chambers and facilitates physicians' abilities to deliver an optimal ablation strategy.
Through continuous research, Biosense Webster, Inc. is committed to reducing the rising healthcare burden of arrhythmias in the Asia Pacific region.
*The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson's Medical Devices segment.
About Johnson & Johnson Medical Devices Companies
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people's healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
About Biosense Webster, Inc.
Biosense Webster, Inc., is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of the Johnson & Johnson Family of Companies, the specialized medical-technology company is headquartered in Irvine, Ca., and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. Learn more at www.biosensewebster.com and connect on LinkedIn and Twitter.
Photo - https://photos.prnasia.com/prnh/20200715/2858294-1?lang=0
